ALKA-372-001 Archives - Medical Conferences

Updated results confirm efficacy and safety of entrectinib in patients with NTRK fusion-positive NSCLC

Presented By

Prof. Byoung Chul Cho, Yonsei Cancer Center Seoul, South Korea

Trial

Phase 1/2, ALKA-372-001, STARTRK-1, STARTRK-2

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:40

Presented By

Dr Giles W. Robinson, St. Jude Children’s Research Hospital, USA

Conference

ASCO 2019

Type

Peer-reviewed article

15 July 2019 14:20

Trial

STARTRK-2, STARTRK-1, ALKA-372-001

Conference

WClC 2018

Type

Peer-reviewed article

21 November 2018 21:57